Clinical Trial

Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients

Study acronym: SWIVEL
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 12, 2026 (before its estimated August 5, 2026 completion). Its status may not reflect the trial's current state.
Summary
Researchers have learned that about 50% of women do not finish the standard 5-year breast cancer treatment with an aromatase inhibitor. An aromatase inhibitor is hormone therapy that lowers the chance of breast cancer coming back (recurring) after surgery by blocking an enzyme in fat tissue called aromatase; aromatase changes other hormones in the body to estrogen. Women who do not complete the standard 5-year treatment are at higher risk of their cancer coming back. The goal of this research is to prevent breast cancer from coming back after surgery by helping women to stay on treatment with aromatase inhibitors. Researchers believe the best path to help women to stay on treatment is to create a better way to manage (control) side effects.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-16.
Status change: Not Yet Recruiting → Recruiting 2026-02-10
Trial Details
NCT Number NCT07071038
Lead Sponsor Dartmouth-Hitchcock Medical Center
Conditions Breast Cancer, Adjuvant Treatment, Early Stage Breast Cancer
Enrollment 62 participants
Start Date 2025-10-17
Primary Completion 2026-08-05 (estimated)
Study Completion 2027-08-05 (estimated)
Updated on ClinicalTrials.gov 2026-02-12